Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Change in Receivables (2024 - 2025)

Silence Therapeutics' Change in Receivables history spans 2 years, with the latest figure at -$30000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables fell 104.91% year-over-year to -$30000.0; the TTM value through Dec 2025 reached -$1.0 million, down 213.27%, while the annual FY2025 figure was -$1.0 million, 213.27% down from the prior year.
  • Change in Receivables for Q4 2025 was -$30000.0 at Silence Therapeutics, up from -$62000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $10.0 million in Q1 2024 and bottomed at -$8.0 million in Q2 2024.